使用液相色谱-质谱联用检测创伤患者直接口服抗凝药:药物重整的新方法
本研究在大型城市一级创伤中心开展,纳入356例受试者(10例健康对照、19例已知阳性或阴性对照、327例65岁以上创伤患者),开发液相色谱-质谱联用法检测阿哌沙班、利伐沙班和达比加群,并与电子病历标准药物重整记录的DOAC使用情况比较。356例中39例(10.96%)使用DOAC:阿哌沙班21例、利伐沙班14例、达比加群4例。检测任何DOAC的总体准确率98.60%,敏感度94.87%,特异度99.05%(PPV 92.50%,NPV 99.37%);阿哌沙班敏感度90.48%、特异度99.10%(PPV 86.36%,NPV 99.40%),有3例假阳性和2例假阴性;达比加群和利伐沙班敏感度与特异度均为100%。作者认为该检测高度准确,但需进一步研究确认其临床效用及在创伤患者药物重整中的价值。
要点
- 液相色谱-质谱联用法检测创伤患者任何DOAC的总体准确率98.60%,敏感度94.87%,特异度99.05%(PPV 92.50%,NPV 99.37%)。
- 阿哌沙班检测敏感度90.48%、特异度99.10%(PPV 86.36%,NPV 99.40%),出现3例假阳性和2例假阴性。
- 达比加群和利伐沙班检测的敏感度与特异度均为100%。
- 356例受试者中39例(10.96%)使用DOAC:阿哌沙班21例、利伐沙班14例、达比加群4例。
- 作者认为该检测在创伤患者中检测DOAC高度准确,但需进一步研究确认其临床效用及对药物重整的价值。
适用人群与场景
- 327例65岁以上、在本大型城市一级创伤中心接受评估的创伤患者,另设10例健康对照和19例已知阳性或阴性对照。
研究设计与关键结果
- 研究类型为诊断试验,共纳入356例受试者,包括10例健康对照、19例已知阳性或阴性对照和327例65岁以上创伤患者,样本来自大型城市一级创伤中心。
- 356例中39例(10.96%)使用DOAC:阿哌沙班21例、利伐沙班14例、达比加群4例。
- 检测任何DOAC的总体准确率98.60%,敏感度94.87%,特异度99.05%,PPV 92.50%,NPV 99.37%。
- 阿哌沙班检测敏感度90.48%,特异度99.10%,PPV 86.36%,NPV 99.40%;有3例假阳性和2例假阴性。
- 达比加群和利伐沙班检测的敏感度与特异度均为100%。
证据类型、等级与局限
- 证据类型为诊断试验,证据等级为level III。
- 局限:作者指出需进一步研究确认该LCMS检测的临床效用及其在创伤患者药物重整中的价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Accurate medication reconciliation in trauma patients is essential but difficult. Currently, there is no established clinical method of detecting direct oral anticoagulants (DOACs) in trauma patients. We hypothesized that a liquid chromatography-mass spectrometry (LCMS)-based assay can be used to accurately detect DOACs in trauma patients upon hospital arrival.
METHODS: Plasma samples were collected from 356 patients who provided informed consent including 10 healthy controls, 19 known positive or negative controls, and 327 trauma patients older than 65 years who were evaluated at our large, urban level 1 trauma center. The assay methodology was developed in healthy and known controls to detect apixaban, rivaroxaban, and dabigatran using LCMS and then applied to 327 samples from trauma patients. Standard medication reconciliation processes in the electronic medical record documenting DOAC usage were compared with LCMS results to determine overall accuracy, sensitivity, specificity, and positive and negative predictive values (PPV, NPV) of the assay.
RESULTS: Of 356 patients, 39 (10.96%) were on DOACs: 21 were on apixaban, 14 on rivaroxaban, and 4 on dabigatran. The overall accuracy of the assay for detecting any DOAC was 98.60%, with a sensitivity of 94.87% and specificity of 99.05% (PPV, 92.50%; NPV, 99.37%). The assay detected apixaban with a sensitivity of 90.48% and specificity of 99.10% (PPV, 86.36%; NPV 99.40%). There were three false-positive results and two false-negative LCMS results for apixaban. Dabigatran and rivaroxaban were detected with 100% sensitivity and specificity.
CONCLUSION: This LCMS-based assay was highly accurate in detecting DOACs in trauma patients. Further studies need to confirm the clinical efficacy of this LCMS assay and its value for medication reconciliation in trauma patients.
LEVEL OF EVIDENCE: Diagnostic Test, level III.
参考来源
- Jayaraman S, DeAntonio JH, Leichtle SW, et al. Detecting direct oral anticoagulants in trauma patients using liquid chromatography-mass spectrometry: A novel approach to medication reconciliation. J Trauma Acute Care Surg. 2020. PMID: 31688825. doi:10.1097/TA.0000000000002527
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。